TREA

79340795 - BRC

Follow

Information

  • Trademark
  • 79340795
  • Serial Number
    79340795
  • Filing Date
    February 25, 2022
    2 years ago
  • Transaction Date
    June 05, 2024
    2 days ago
  • Status Date
    June 04, 2024
    3 days ago
  • Published for Opposition Date
    July 09, 2024
    a month from now
  • Location Date
    June 04, 2024
    3 days ago
  • Status Code
    681
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    LEASER, ANDREW C
  • Attorney Docket Number
    571398
    Attorney Name
    Andrew D. Price & Paula E. Hopkins
    Law Office Assigned Location Code
    M80
  • Owners
Information
Mark Drawing Code
4
Mark Identification
BRC
Case File Statements
  • GS0051: Pharmaceuticals, for use in the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for use in the treatment and prevention of metabolic disease, urology and renal disease, in the cardiovascular field, in the field of hematology, for use in the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of ophthalmology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and/or prevention of respiratory disease; pharmaceutical products and preparations for the treatment and/or prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and/or prevention of metabolic disease; pharmaceutical products and preparations for the treatment and/or prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imaging, namely, clinical imaging agents; pharmaceutical products and preparations for the treatment and/or prevention of renal disease; pharmaceutical products and preparations for the treatment and/or prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and/or prevention of muscular skeletal disease; none of the foregoing in the field of palliative care
  • GS0441: Pharmaceutical compounding services; advisory services relating to pharmaceuticals; pharmaceutical consultation and providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in the field of respiratory disease; pharmaceutical compounding services in the field of cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and/or prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; information, consultancy and advisory services relating to the aforesaid; none of the foregoing in the field of palliative care
  • GS0421: Scientific and technological services and research and design relating thereto, namely, scientific research, new product design services, and new study design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; industrial analysis and research services in the fields of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; pharmaceutical research and development services; medical research and development services; pharmaceutical testing and medical and scientific research, namely, conducting clinical trials for others; medical and scientific research, namely, conducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; information consultancy and advisory services relating to the aforesaid; none of the foregoing in the field of palliative care
Case File Event Statements
  • 5/20/2022 - 2 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 5/19/2022 - 2 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR
  • 5/24/2022 - 2 years ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 9/7/2022 - a year ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 9/10/2022 - a year ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 9/11/2022 - a year ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 9/24/2022 - a year ago
    7 - CHANGE OF NAME/ADDRESS REC'D FROM IB Type: ADCH
  • 10/28/2022 - a year ago
    8 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 10/28/2022 - a year ago
    9 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 11/21/2022 - a year ago
    10 - REFUSAL PROCESSED BY IB Type: RFNT
  • 4/26/2023 - a year ago
    11 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 4/26/2023 - a year ago
    12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 4/26/2023 - a year ago
    13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 10/25/2023 - 7 months ago
    17 - NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Type: OPNR
  • 5/22/2023 - a year ago
    14 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 5/22/2023 - a year ago
    15 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 5/22/2023 - a year ago
    16 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3
  • 10/25/2023 - 7 months ago
    18 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 11/12/2023 - 6 months ago
    19 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX
  • 12/1/2023 - 6 months ago
    20 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 1/8/2024 - 5 months ago
    21 - SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Type: RCCK
  • 1/29/2024 - 4 months ago
    23 - FINAL REFUSAL E-MAILED Type: GNFR
  • 1/29/2024 - 4 months ago
    22 - FINAL REFUSAL WRITTEN Type: CNFR
  • 1/29/2024 - 4 months ago
    24 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 5/29/2024 - 9 days ago
    26 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 6/1/2024 - 6 days ago
    28 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 5/29/2024 - 9 days ago
    27 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 5/29/2024 - 9 days ago
    25 - TEAS REQUEST FOR RECONSIDERATION RECEIVED Type: ERFR